In a report released today, Andrew Fein from H.C. Wainwright maintained a Hold rating on Eloxx Pharmaceuticals (ELOX), with a price target of $3.00. The company’s shares closed last Friday at $2.62.
According to TipRanks.com, Fein is a 4-star analyst with an average return of 4.8% and a 42.9% success rate. Fein covers the Healthcare sector, focusing on stocks such as Proteostasis Therapeutics, Deciphera Pharmaceuticals, and Phasebio Pharmaceuticals.
Eloxx Pharmaceuticals has an analyst consensus of Hold, with a price target consensus of $3.00.
See today’s analyst top recommended stocks >>
The company has a one-year high of $8.16 and a one-year low of $1.44. Currently, Eloxx Pharmaceuticals has an average volume of 45.58K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Eloxx Pharmaceuticals, Inc. engages in the development of novel ribonucleic acid modulating drug candidates. The firm focuses on the the formulation of medicines to treat rare and ultra-rare premature stop codon diseases. It operates through the United States and Israel geographical segments. Its product includes ELX-02, a small molecule drug designed to restore production of full-length functional proteins which treats cystic fibrosis and cystinosis. The company was founded on December 19, 2017 and is headquartered in Waltham, MA.
